NCT02794155 - Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1) | Biotech Hunter

Enrollment

157

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 28, 2018

Study Completion Date

June 15, 2018

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

HDV Insulin Lispro

HDV Insulin Lispro: \~1% of the Insulin Lispro is bound to HDV (Hepatocyte Directed Vesicle)

DRUG

Insulin LISPRO

Insulin Lispro: no bound insulin

Trial Locations (21)

13210

SUNY Upstate Medical University, Syracuse

30076

Endocrine Research Solutions, Inc., Roswell

30318

Atlanta Diabetes Associates, Atlanta

32127

Progressive Medical Research, Port Orange

32174

Ormond Medical Arts Pharmaceutical Research Center, Ormond Beach

33147

Advanced Pharma CR, LLC, Miami

60124

Associates in Endocrinology, Elgin

73072

LION Research, Norman

77095

Endocrine and Psychiatry Center, Houston

78229

Clinical Trials of Texas, Inc., San Antonio

80209

Creekside Endocrine Associates, PC, Denver

83404

Rocky Mountain Diabetes & Osteoporosis Center, PA, Idaho Falls

89052

Desert Endocrinology Clinical Research Center, Henderson

90057

National Research Institute, Los Angeles

91324

California Medical Research Associates Inc., Northridge

92780

Orange County Research Center, Tustin

92882

Hope & Wellness Clinical Trials, Inc., Corona

94070

Bay Area Clinical Research, San Carlos

94401

Mills-Peninsula Health Services, San Mateo

98057

Rainier Clinical Research Center, Inc., Renton

01655

University of Massachusetts Memorial Hospital, Worcester